This study investigated the effectiveness of Janus kinase (JAK) inhibitors in rheumatoid arthritis (RA). They found that JAK inhibitors were more effective than conventional RA drugs. 

This review looked at whether SGLT2 inhibitors increase the risk of ketoacidosis in patients with type 2 diabetes (T2D). It found that long-term use of these medications increases the risk of ketoacidosis, particularly for older patients.

This study investigated if reducing the doses (tapering) of biologic drugs maintains effectiveness in patients with rheumatoid arthritis (RA). 

They found that drug tapering maintained low disease activity (LDA) and remission while reducing side effects and costs.

This article made recommendations for patients with diabetes on how to manage their health during the COVID-19 pandemic.

This study looked at the outcomes of patients with type 2 diabetes (T2D) who were diagnosed with COVID-19. It found that patients with well-controlled blood glucose had fewer medical interventions and notably better survival.

This study investigated ocular (eye) conditions (OCs) in patients with rheumatoid arthritis (RA). They found that OCs affect approximately 20% of patients with RA.

This study compared two types of percutaneous nephrolithotomy (PCNL) procedure to treat patients with kidney stones. The results showed that miniaturized PCNL (mPCNL) was slightly more effective and as safe as standard PCNL (sPCNL).

This study investigated how rheumatoid arthritis (RA)and its treatment may affect bone mineral density (BMD). They found that RA was associated with a reduced BMD and an increased risk of falls and fractures. 

This study wanted to find out if people with type 1 diabetes who use insulin pumps have fewer changes in their blood glucose control than those who use multiple daily injections. The study found that the patients who used insulin pumps had fewer changes in blood glucose control than those on multiple daily injections.

This study looked at the effect of dapagliflozin (Farxiga) on kidney disease in patients with type 2 diabetes. It found patients treated with dapagliflozin were significantly less likely to have a decline in kidney function.